genes

G6PD

G6PD is the rate-limiting enzyme of the pentose phosphate pathway, essential for the production of NADPH. It is the primary protector of red blood cells against oxidative stress, and its deficiency is the most common enzyme defect in humans, affecting over 400 million people.

schedule 10 min read update Updated February 25, 2026

Key Takeaways

  • G6PD provides the "shield" (NADPH) that protects red blood cells from popping.
  • It is an X-linked gene, meaning deficiency is much more common in men.
  • Deficiency leads to sudden anemia (hemolysis) triggered by fava beans, certain drugs, or infection.
  • Variants are highly common in malaria-endemic regions as they provide a survival advantage.

Basic Information

Gene Symbol
G6PD
Full Name
Glucose-6-Phosphate Dehydrogenase
Also Known As
G6PD1
Location
Xq28
Protein Type
Metabolic Enzyme
Protein Family
G6PD family

Related Isoforms

Key SNPs

rs5030868 Exonic (G6PD Mediterranean)

The most common severe deficiency variant (Class II); leads to extremely low enzyme activity and high sensitivity to oxidative triggers.

rs1050828 Exonic (G6PD A-)

A moderate deficiency variant (Class III); very common in individuals of African ancestry. Enzyme activity is normal in young RBCs but declines rapidly as cells age.

rs1050829 Exonic (G6PD A)

Often found in combination with rs1050828; associated with a milder reduction in enzyme activity compared to the Mediterranean variant.

Overview

G6PD (Glucose-6-Phosphate Dehydrogenase) encodes the first and rate-limiting enzyme of the pentose phosphate pathway. This metabolic route is the body’s primary source of NADPH—a critical molecule used for fatty acid synthesis and, most importantly, for maintaining the pool of reduced glutathione. Glutathione is the body’s "master antioxidant," responsible for neutralizing reactive oxygen species (ROS) before they can damage cellular structures.

For red blood cells (RBCs), G6PD is a matter of survival. Unlike other cells, RBCs lack a nucleus and mitochondria, meaning they rely entirely on G6PD for their antioxidant defense. In individuals with G6PD deficiency, the RBCs are "brittle" under oxidative pressure. When exposed to certain triggers—such as the "vicine" in fava beans or oxidative medications—the hemoglobin inside the cells clumps together, causing the RBCs to rupture and leading to acute hemolytic anemia.

Conceptual Model

A simplified mental model for the pathway:

Trigger
The Spark
Fava beans / Meds
G6PD
The Firewall
Produces NADPH
GSH
The Extinguisher
Neutralizes ROS
RBC
The Building
Structural integrity

G6PD provides the fuel for the "firewall" that keeps the red blood cell from burning up under stress.

Core Health Impacts

  • Antioxidant Defense: The sole source of NADPH in red blood cells required to maintain reduced glutathione
  • Hemoglobin Stability: Prevents the oxidative denaturation of hemoglobin into "Heinz bodies"
  • Infection Resistance: G6PD variants provide a significant survival advantage against severe malaria
  • Lipid Synthesis: Provides NADPH for the production of cholesterol and fatty acids in the liver and brain
  • Nitric Oxide Balance: NADPH is a cofactor for nitric oxide synthase, impacting vascular health and dilation

Protein Domains

NADP+ Binding Site

A structural motif (the Rossmann fold) that captures the coenzyme required for the reaction.

Substrate Binding Pocket

Specific region that recognizes and binds Glucose-6-Phosphate to initiate the pathway.

Dimerization Interface

G6PD must form a dimer or tetramer to be catalytically active; many mutations disrupt this assembly.

Upstream Regulators

NADP+ Levels Activator

The primary allosteric regulator; low levels of NADPH (high NADP+) signal the enzyme to speed up.

Oxidative Stress Activator

Acute presence of ROS consumes NADPH, indirectly triggering increased G6PD activity.

Insulin Activator

Transcriptional inducer of G6PD in the liver to provide NADPH for fat synthesis after a meal.

Glucose-6-Phosphate Activator

The primary chemical substrate provided by hexokinase in the first step of glycolysis.

Estrogen Modulator

Reported to enhance G6PD expression, which may contribute to the antioxidant resilience of females.

Downstream Targets

NADPH Production Activates

The definitive output of the G6PD reaction; the "currency" of cellular reducing power.

Reduced Glutathione (GSH) Activates

NADPH is required to "recharge" oxidized glutathione back into its active antioxidant form.

ROS Neutralization Activates

Through the glutathione system, G6PD activity stops the build-up of damaging free radicals.

Hemoglobin Integrity Activates

Protects the iron-containing heme groups from being permanently damaged by oxidation.

Ribose-5-Phosphate Activates

A downstream product of the pathway needed for the synthesis of DNA and RNA.

Role in Aging

G6PD is a master regulator of "oxidative lifespan." As the primary source of cellular reducing power, its efficiency determines how well our tissues can withstand the cumulative oxidative damage that drives the biological aging process.

RBC Aging

The G6PD A- variant is a classic model of "accelerated cell aging," where the enzyme survives only half as long as the cell itself.

Cumulative Damage

Declining G6PD activity with age reduces the "antioxidant buffer," allowing ROS to damage proteins and DNA more easily.

Vascular Longevity

Optimal G6PD function is required for endothelial health; its decline is linked to reduced nitric oxide and arterial stiffening.

Cognitive Reserve

The brain is highly oxidative; G6PD-mediated NADPH production is essential for protecting neurons from age-related decay.

Metabolic Resilience

Age-related changes in G6PD activity in the liver and adipose tissue can alter the body's ability to manage lipids and glucose.

Centenarian Signature

High-activity G6PD variants are sometimes enriched in long-lived populations, suggesting it is a "longevity-enabling" gene.

Disorders & Diseases

G6PD Deficiency

The most common human enzyme defect. Categorized into WHO classes based on severity (Class I-IV). Can cause lifelong jaundice or acute crises.

Prevalence: High in African, Mediterranean, and Asian groups

Acute Hemolytic Anemia

Triggered by oxidative stress. Symptoms include dark urine (hemoglobinuria), fatigue, and back pain as RBCs rupture.

Favism

A specific and severe hemolytic reaction to the ingestion of fava beans (Vicia faba), which contain the oxidant vicine.

Neonatal Jaundice

G6PD deficient newborns are at high risk for severe jaundice (bilirubin build-up), which can lead to brain damage (kernicterus) if not treated.

Chronic Non-Spherocytic Anemia

Caused by rare Class I mutations that are so severe the RBCs are breaking down constantly, even without an external trigger.

The Malaria Trade-off

G6PD deficiency is a classic example of balanced selection. The malaria parasite (Plasmodium) cannot survive well in a G6PD-deficient "brittle" red blood cell, giving carriers a survival advantage in infected regions.

Interventions

Supplements

Vitamin E

A fat-soluble antioxidant that may help stabilize RBC membranes in individuals with mild G6PD deficiency.

Selenium

Required for glutathione peroxidase, the enzyme that uses the GSH produced via the G6PD pathway.

Alpha-Lipoic Acid

Studied for its ability to regenerate other antioxidants and potentially support the cellular REDOX balance.

N-Acetyl Cysteine (NAC)

A precursor to glutathione; while helpful, its benefits in G6PD deficiency are limited by the lack of NADPH needed to recycle it.

Lifestyle

Trigger Avoidance

The single most important intervention; G6PD-deficient individuals must avoid fava beans and a specific list of oxidative drugs.

Infection Prevention

Infections are the most common trigger for hemolysis in G6PD deficiency, as the "oxidative burst" of white cells damages the RBCs.

Prompt Jaundice Care

Immediate phototherapy for G6PD-deficient newborns is critical to prevent the neurological complications of high bilirubin.

Genetic Counseling

As an X-linked trait, understanding the inheritance pattern is vital for family planning and neonatal safety.

Medicines

Primaquine / Tafenoquine

Anti-malarial drugs that are the most famous "forbidden" triggers; they cause rapid hemolysis in G6PD-deficient patients.

Rasburicase

A uric-acid-lowering drug that is absolutely contraindicated in G6PD deficiency due to the risk of fatal hemolysis.

Nitrofurantoin / Sulfa Drugs

Common antibiotics that can trigger hemolytic episodes in individuals with more severe G6PD variants.

Methylene Blue

Used for methemoglobinemia but can be dangerous in G6PD deficiency as it requires NADPH to be effective and safe.

Lab Tests & Biomarkers

Functional Status

G6PD Enzyme Activity Assay

Measures the actual chemical speed of the enzyme in the blood. Must not be performed during an active hemolytic flare.

Quantitative Spectrophotometry

The gold-standard functional test, reporting results in Units per gram of Hemoglobin (U/g Hb).

Genetic Screening

G6PD Genotyping

Identifies the specific mutation (e.g., Mediterranean, A-, Canton). Essential for confirming carrier status in females.

Newborn G6PD Screening

Standard in many countries to prevent neonatal jaundice and kernicterus.

Acute Markers

Peripheral Blood Smear (Heinz Bodies)

Visualizes the clumps of damaged hemoglobin that form inside RBCs during an oxidative crisis.

Serum Bilirubin / LDH

Classic markers of hemolysis; LDH rises and haptoglobin falls as RBCs are destroyed.

Hormonal Interactions

Estrogen Protective

Reported to increase G6PD activity; may explain why female "heterozygotes" are often less symptomatic than predicted.

Insulin Activator

Directly upregulates G6PD transcription in the liver to provide the NADPH needed for lipogenesis.

Cortisol Modulator

Chronic high stress can alter the metabolic priority of the pentose phosphate pathway.

Growth Hormone Regulator

Supports the general metabolic reserve and protein synthesis required for enzyme maintenance.

Deep Dive

Network Diagrams

G6PD and the Antioxidant Shield

The Antioxidant Shield: G6PD and NADPH

To understand G6PD, one must view the red blood cell as a ship sailing through a sea of corrosive saltwater (oxidative stress). For the ship to survive, it must constant pump the saltwater back out. G6PD is the powerhouse that provides the energy for those pumps.

The Reducing Currency: G6PD is the rate-limiting enzyme of the pentose phosphate pathway. Its primary job is to take energy from sugar and use it to create NADPH. NADPH is the cellular “reducing currency” needed to keep the body’s master antioxidant, glutathione, in its active, reduced state.

The RBC Bottleneck: While other cells have many ways to make NADPH, red blood cells rely only on G6PD. This makes them the weak link in the body’s antioxidant system. Without a constant stream of NADPH from G6PD, the glutathione “pumps” fail, and oxidative damage begins to eat away at the red blood cell from the inside out.

The Genetic Clock: Class II vs. Class III

The severity of G6PD deficiency is determined by how fast the enzyme “ages” after the red blood cell is born.

The Moderate Variant (G6PD A-): Common in African populations, this variant creates an enzyme that is stable for about 15-20 days. Since RBCs live for 120 days, the young cells are healthy, but the “elderly” cells are defenseless. This results in a moderate, self-limiting hemolytic anemia.

The Severe Variant (G6PD Mediterranean): This variant creates an enzyme so unstable it only works for a few hours. Nearly all the red blood cells in these individuals are undefended. This is why Mediterranean carriers are at such high risk for Favism—a catastrophic rupture of red cells after eating fava beans, which contain high levels of oxidizing chemicals.

The Malaria Shield: An Evolutionary Trade-off

G6PD deficiency is the most common enzyme defect in humans, affecting over 400 million people. Why would such a dangerous “weakness” be so common? The answer is malaria.

The Hostile Environment: The malaria parasite (Plasmodium falciparum) is extremely sensitive to oxidative stress. It needs a healthy, robust red blood cell to multiply. A G6PD-deficient cell is “brittle” and prone to oxidative bursts. When the parasite enters, the cell often ruptures before the parasite can finish its lifecycle.

Survival of the Fragile: In regions where malaria was a leading cause of death, being G6PD-deficient was a survival advantage. You were more likely to survive childhood and pass on your genes. This makes G6PD a classic example of balanced selection, where a genetic “defect” is preserved because it protects against a far more lethal environmental threat.

Practical Note: The Danger of the Flash

Hemolysis is sudden. For a G6PD-deficient individual, an oxidative crisis can occur within hours of exposure to a trigger. This is not a slow decline; it is a rapid "popping" of red cells that can lead to life-threatening anemia if the trigger is not removed immediately.

Check the list. If you are G6PD deficient, you must have a "forbidden drug list" provided by your doctor. Common over-the-counter medicines like Aspirin (in high doses) or specific antibiotics can be dangerous. Always inform your surgeon or anesthesiologist of your G6PD status.

Relevant Research Papers

Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.

Luzzatto et al. (2016) The Lancet

The definitive modern review of the molecular genetics, clinical manifestations, and global health impact of G6PD deficiency.

Tishkoff et al. (2001) Science

Pivotal paper tracing the independent evolution of different G6PD deficiency alleles as a response to malaria selection.

Jain et al. (2004) Journal of Clinical Investigation
PubMed Free article DOI

Demonstrated the essential role of G6PD beyond the RBC, linking it to cardiovascular and nitric oxide health.

Au et al. (2000) Structure

Provided the first high-resolution crystal structure of G6PD, revealing how pathogenic mutations disrupt the enzyme dimer.

Arese et al. (2012) Blood Reviews
PubMed Free article DOI

Characterized the metabolic and structural changes in G6PD-deficient RBCs that mimic the natural aging process.